Sermorelin: What the Research Looks At
Updated 2026-09-03
An education-first look at sermorelin: its history as an approved product, current compounded use, and regulatory status. Not medical advice.
What it is
Sermorelin is a growth hormone-releasing hormone (GHRH) analog, a shortened, active fragment of the natural hormone that stimulates the pituitary gland to release its own growth hormone. Sermorelin acetate has an unusual history among the peptides discussed on this site: a version was previously marketed in the United States under the brand name Geref, with FDA approval primarily for diagnostic testing of growth hormone response and for pediatric growth hormone deficiency, before the brand-name product was discontinued from the market. Today, sermorelin sold through compounding pharmacies is a different matter, since it is prepared individually rather than manufactured as the original approved product and is not currently sold under a currently active label that received FDA approval.
How it is studied
Sermorelin's original approval was supported by clinical studies conducted for its diagnostic and pediatric growth hormone deficiency indications, published decades ago and reflected in historical FDA drug records available through the Drugs@FDA database. More recent research on GHRH analogs, including sermorelin used in adult and general-wellness contexts, is considerably thinner and largely limited to smaller studies and case series rather than a large, modern, placebo-controlled trial program. A search of PubMed shows continued academic interest in GHRH analogs broadly, but researchers in this space are careful to distinguish sermorelin's original, narrowly approved uses from its current, much broader off-label and compounded use in adult wellness contexts.
What the research looks at
Researchers have looked at GHRH analogs like sermorelin in connection with growth hormone and IGF-1 response patterns, sleep-related hormone release, and age-related changes in pituitary function. These areas are described as ongoing investigation rather than settled outcomes for a general adult population using a compounded product, and findings from sermorelin's original, narrow diagnostic and pediatric indications should not be assumed to transfer automatically to a different population using it for a different purpose.
Regulatory status
Sermorelin's regulatory history is unusual: it was once a product approved by the FDA, marketed under the
brand name Geref, discontinued from the market for commercial reasons according to public
FDA records, rather than pulled for a new safety finding. Compounded sermorelin sold
today is not the same product and is not currently marketed under an active approved
label. As a compounded substance, it sits under the general 503A and 503B compounding
framework that applies to other peptides in this category, and FDA compounding policy has
been subject to periodic review (see /regulation/fda-category-2-list-explained/ and
/regulation/503a-vs-503b-compounding-explained/). Readers should check the current
/regulation/fda-compounding-rulings-2026-update/ page rather than assume a fixed status.
Safety signals reported
Historical clinical data from sermorelin's original approved indications documented a defined side-effect profile for that specific product and those specific patient populations, available through public FDA drug records. Safety data for today's compounded sermorelin, used more broadly in adult wellness contexts, is far less well characterized, since it has not been the subject of the same controlled trial program. Growth hormone-releasing peptides as a class carry theoretical considerations around blood sugar regulation and fluid balance that a licensed provider is positioned to evaluate for an individual's health history. This is not medical advice. Discuss any decision about sermorelin, historical or compounded, with a licensed healthcare provider first.
Questions to ask a clinician
- How does compounded sermorelin sold today differ from the discontinued, approved Geref product?
- Does my situation resemble any population studied in sermorelin's original approved indications?
- What effect could this have on blood sugar or fluid balance given my current health conditions?
- How would you verify the purity and identity of a compounded product before I considered it?
- What monitoring would you recommend if this were part of a broader conversation about growth hormone-related therapy?
- If a diagnostic growth hormone stimulation test is relevant to me, what does that process involve today?
FAQ
Was sermorelin ever an approved medication? Yes. A sermorelin acetate product was previously marketed under the brand name Geref and had FDA approval, primarily for diagnostic testing of growth hormone response and for pediatric growth hormone deficiency. The brand-name product was later discontinued from the market for commercial reasons unrelated to a new safety finding, according to public FDA drug-discontinuation records.
Is compounded sermorelin the same as the discontinued Geref product? No. Today's compounded sermorelin is prepared by individual pharmacies rather than manufactured as the original approved product, and it is not currently backed by a currently active label that received FDA approval.
What is sermorelin's mechanism? Sermorelin is a growth hormone-releasing hormone (GHRH) analog, meaning it is designed to stimulate the body's own pituitary gland to release growth hormone rather than supplying growth hormone directly.
Is sermorelin legal to buy in the United States? Compounded sermorelin is not currently sold under a currently active label that received FDA approval, and its status under 503A and 503B compounding rules has been subject to periodic review. Readers should check current FDA guidance rather than assume a fixed legal status.
Sources
- FDA, Drugs@FDA database search tool -- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
- FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503B -- https://www.fda.gov/drugs/human-drug-compounding/fda-issues-list-bulk-drug-substances-outsourcing-facilities-may-use-compound-under-section-503b
- PubMed, search results for "sermorelin growth hormone releasing hormone" -- https://pubmed.ncbi.nlm.nih.gov/?term=sermorelin+growth+hormone+releasing+hormone
Disclaimer
This content is for general education only and is not medical advice, diagnosis, or treatment. Peptide Briefs does not sell peptides and does not recommend any specific product, dose, or protocol. These statements have not been evaluated by the Food and Drug Administration. Always talk with a licensed healthcare provider before starting, stopping, or changing any therapy.